G. Koehne

发表

Rituximab therapy of lymphoma is enhanced by orally administered (1-->3),(1-->4)-D-beta-glucan.

A. Vickers, N. Cheung, S. Modak, 2005, Leukemia research.

Cancer–Testis Antigen 7 Expression and Immune Responses Following Allogeneic Stem Cell Transplantation for Multiple Myeloma

S. Gnjatic, A. Jungbluth, R. O'reilly, 2014, Cancer Immunology Research.

Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors.

E. Pamer, G. Heller, B. Dupont, 2002, Blood.

Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation.

J. Wolchok, J. Goldberg, M. Perales, 2012, Blood.

Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes

Michel Sadelain, Steven M. Larson, Pat Zanzonico, 2003, Nature Biotechnology.

Rapid selection of antigen-specific T lymphocytes by retroviral transduction.

M. Sadelain, R. O'reilly, G. Koehne, 2000, Blood.

Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients’ monitoring after transplantation

S. Devlin, A. Lesokhin, E. Riedel, 2013, Bone Marrow Transplantation.

Ex Vivo CD34+-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response.

J. Goldberg, M. Perales, M. V. D. van den Brink, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation.

J. Goldberg, M. Perales, S. Devlin, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Re-vaccination following Autologous Hematopoietic Stem Cell Transplantation is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance

Anp-Bc, M. Perales, S. Devlin, 2019 .

Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant

E. Robilotti, Cesar J. Figueroa, S. Morjaria, 2018, Science Translational Medicine.

Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections

R. O'reilly, S. Prockop, E. Doubrovina, 2016, Bone Marrow Transplantation.

Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.

M. Perales, S. Devlin, A. Lesokhin, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Chemotherapy-only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit ATG followed by Allogeneic T-cell Depleted Hematopoietic Stem Cell Transplants for the Treatment of Myeloid Malignancies

M. Perales, K. Hsu, James W. Young, 2018 .

A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.

M. Perales, M. V. D. van den Brink, K. Hsu, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

after allogeneic stem cell transplantation Recombinant human interleukin-7 (CYT107) promotes T-cell recovery

J. Wolchok, J. Goldberg, M. Perales, 2012 .

Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation.

A. Zelenetz, M. Perales, S. Devlin, 2021, Blood advances.

Recombinant human interleukin-7 ( CYT 107 ) promotes T-cell recovery after allogeneic stem cell transplantation

J. Wolchok, J. Goldberg, M. Perales, 2012 .

Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency*

S. Devlin, A. Lesokhin, A. Ogunniyi, 2017, Leukemia & lymphoma.

Pre-salvage ISS and Other Important Outcome Associations in CD34 Selected Allogeneic Hematopoietic Stem Cell Transplant for Multiple Myeloma.

M. Perales, O. Landgren, S. Giralt, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation

S. Jhanwar, R. Levine, S. Devlin, 2017, Leukemia & lymphoma.

Opaganib in Coronavirus Disease 2019 Pneumonia: Results of a Randomized, Placebo-Controlled Phase 2a Trial

M. Levitt, K. Winthrop, H. Minkowitz, 2022, Open forum infectious diseases.

Opaganib in COVID-19 pneumonia: Results of a randomized, placebo-controlled Phase 2a trial

M. Levitt, K. Winthrop, H. Minkowitz, 2021, medRxiv.

Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis.

N. Kröger, A. Zander, J. Dierlamm, 1996, Bone marrow transplantation.

Cancer-testis antigen expression and immunogenicity in AL amyloidosis

D. Seldin, S. Gnjatic, A. Jungbluth, 2012, Blood Cancer Journal.

Long-term prognosis for 1-year relapse-free survivors of CD34 cell–selected allogeneic hematopoietic stem cell transplantation: a landmark analysis

M. Perales, M. V. D. van den Brink, S. Devlin, 2017, Bone Marrow Transplantation.

Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myeloid Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease.

M. Perales, James W. Young, S. Giralt, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Proteomic profiling in plasma cell disorders: a feasibility study

S. Devlin, A. Lesokhin, Minal A. Patel, 2017, Leukemia & lymphoma.

Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia.

R. O'reilly, S. Prockop, E. Doubrovina, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Biomarkers of Cardiotoxicity Among Multiple Myeloma Patients Subsequently Treated with Proteasome Inhibitor Therapy

S. Devlin, A. Lesokhin, I. Grundberg, 2015 .

T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells

R. O'reilly, S. Prockop, E. Doubrovina, 2015, Bone Marrow Transplantation.

Prognostic Factors for Post-Relapse Survival after ex-vivo CD34+-Selected (T cell-depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma.

M. Perales, R. Baser, Arnab Ghosh, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants

R. O'reilly, E. Doubrovina, W. Kollen, 2007, Immunologic research.

CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma.

S. Jagannath, S. Devlin, A. Lesokhin, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: What Place, If Any?

S. Giralt, G. Koehne, 2013, Current Hematologic Malignancy Reports.

Safety and Immunogenicity of the 13-Valent Protein-Conjugated Pneumococcal Vaccine(PCV13) Following Related and Unrelated Hematopoietic Stem Cell Transplantation (HCT)

M. Perales, S. Giralt, T. Small, 2011 .

Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant

J. Teruya-Feldstein, J. Goldberg, M. Perales, 2012, Leukemia & lymphoma.

The Hematopoietic Cell Transplant-Co-Morbidity Index (HCT-CI) Predicts Outcomes After T Cell Depleted (TCD) Allogeneic HCT For AML and MDS

J. Goldberg, M. Perales, S. Devlin, 2013 .

A novel reduced intensity conditioning regimen for patients with high-risk hematological malignancies undergoing allogeneic stem cell transplantation

J. Goldberg, M. Perales, G. Hobbs, 2016, Bone Marrow Transplantation.

T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease.

J. Goldberg, M. Perales, R. Jenq, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

T Cell Depletion as an Alternative Approach for Patients 55 Years or Older Undergoing Allogeneic Stem Cell Transplantation as Curative Therapy for Hematologic Malignancies.

J. Goldberg, M. Perales, James W. Young, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Incidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplant

G. Papanicolaou, M. Perales, S. Devlin, 2015, Leukemia & lymphoma.

Ocular outcomes after treatment of cytomegalovirus (CMV) retinitis using adoptive immunotherapy with CMV-specific cytotoxic T-lymphocytes.

Susanna S. Park, A. Orlin, S. Kiss, 2021, Ophthalmology. Retina.

Donor-derived lymphomatoid papulosis in a stem-cell transplantation recipient.

C. Hedvat, K. Busam, M. Pulitzer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.

J. Teruya-Feldstein, C. Hedvat, G. Heller, 2012, Blood.

Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplant.

J. Teruya-Feldstein, M. Arcila, M. Perales, 2020, The Journal of clinical investigation.

Novel strategies for adoptive therapy following HLA disparate transplants.

R. O'reilly, S. Prockop, E. Doubrovina, 2011, Best practice & research. Clinical haematology.

Phenotype of lymphocyte subsets after autologous peripheral blood stem cell transplantation

Anja Zander, W. Zeller, G. Koehne, 1997, Bone Marrow Transplantation.

Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation.

M. Perales, R. Jenq, M. V. D. van den Brink, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.

D. Scheinberg, T. Dao, R. O'reilly, 2010, Seminars in immunology.

High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia.

M. Perales, M. V. D. van den Brink, S. Devlin, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Double-Unit Cord Blood (CB) Transplantation (DCBT) Combined with Haplo-Identical Peripheral Blood CD34+ Cells (HaploCD34+) Is Associated with Enhanced Neutrophil Recovery, Universal Haplo Rejection, and Frequent Pre-Engraftment Syndrome

M. Perales, James W. Young, A. Scaradavou, 2015 .

Pharmacokinetics and Toxicities after Evomela® (propylene glycol free melphalan) with Autologous Hematopoietic Stem Cell Transplant (AHCT) for Multiple Myeloma and AL Amyloidosis

S. Devlin, S. Giralt, H. Landau, 2017 .

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multip

B. Barlogie, M. Dimopoulos, H. Einsele, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Double-Unit Cord Blood (CB) Transplantation Combined with Haplo-Identical CD34+ Cells Results in 100% CB Engraftment with Enhanced Myeloid Recovery

J. Goldberg, M. Perales, S. Devlin, 2014 .

Double-Unit Cord Blood (CB) Transplantation Combined With Haplo-Identical CD34+ Cell-Selected PBSC Results In 100% CB Engraftment With Enhanced Myeloid Recovery

J. Goldberg, M. Perales, S. Devlin, 2013 .

T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies.

G. Papanicolaou, M. Perales, M. V. D. van den Brink, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation.

M. Perales, S. Devlin, S. Giralt, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies.

M. Perales, S. Devlin, S. Giralt, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.

M. Perales, M. Doubrovin, R. O'reilly, 2010, Blood.

The emergence of WT1-specific T-cell responses following allogeneic T cell-depleted hematopoietic stem cell transplantation and low-dose donor lymphocyte infusions is associated with a graft-vs.- myeloma effect

G. Koehne, E. Tyler, 2013, Oncoimmunology.

WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions.

A. Jungbluth, R. O'reilly, G. Koehne, 2013, Blood.

transplantation and donor lymphocyte infusions depleted hematopoietic stem cell − undergoing allogeneic T cell WT 1-specific T-cell responses in high-risk multiple myeloma patients

A. Jungbluth, R. O'reilly, G. Koehne, 2013 .

Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantation

S. Devlin, A. Lesokhin, Junting Zheng, 2016, Leukemia & lymphoma.

Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy.

Roxanne Y. Williams, R. O'reilly, D. Trivedi, 2004, Blood.

A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.

A. Zelenetz, J. Goldberg, M. Perales, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Phase I Dose Escalation Trial of Donor T Cells Sensitized with Pentadecapeptides of the CMV-pp65 Protein for the Treatment of CMV Infections Following Allogeneic Hematopoietic Stem Cell Transplants.

G. Papanicolaou, M. Perales, James W. Young, 2009 .

Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care

S. Giralt, G. Koehne, 2012, Current opinion in oncology.

Evaluation of acute myeloid leukemia induction regimens in elderly patients

G. Koehne, M. Tadros, T. Zahra, 2020 .

[131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity

S. Larson, R. Blasberg, M. Sadelain, 2006, European Journal of Nuclear Medicine and Molecular Imaging.

Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation.

M. Perales, M. V. D. van den Brink, S. Devlin, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.

S. Devlin, A. Lesokhin, Wendy L. Schaffer, 2014, Blood.

Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood.

A. Lesokhin, L. Ramanathan, O. Landgren, 2018, Clinical biochemistry.

Impact of Toxicity on Survival for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation.

M. Perales, S. Devlin, S. Giralt, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Galinpepimut-S, a WT1-Targeting Immuno-Oncology Treatment, Induces Specific, Robust and Durable Immune Responses (IRs) in Patients (Pts) with High-Risk (HR) Multiple Myeloma (MM)

S. Devlin, A. Lesokhin, O. Landgren, 2017 .

Diagnosis of Extrapulmonary Legionellosis in Allogeneic Hematopoietic Cell Transplant Recipients by Direct 16S Ribosomal Ribonucleic Acid Sequencing and Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry

M. Rosenblum, Yeon Joo Lee, G. Papanicolaou, 2017, Open forum infectious diseases.

A Response Adapted Approach to Induction Treatment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

S. Devlin, A. Lesokhin, Quin Zhou, 2016 .

Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant

G. Papanicolaou, M. Perales, Jinjuan Yao, 2023, The Journal of Clinical Investigation.

Third Party CMV-Specific Cytotoxic T Cells for Treatment of Antiviral Resistant CMV Infection after Hematopoietic Stem Cell Transplant

S. Giralt, R. O'reilly, S. Prockop, 2016 .

Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.

S. Devlin, A. Lesokhin, N. Raje, 2016, Blood.

Phase II Study of Infusional Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma

S. Devlin, A. Lesokhin, S. Giralt, 2012 .

PNH cells are as sensitive to T-cell-mediated lysis as their normal counterparts: implications for the pathogenesis of paroxysmal nocturnal haemoglobinuria.

Lucio Luzzatto, L. Luzzatto, I. Roberts, 2000 .

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study

M. Tomasson, S. Iida, M. Mohty, 2022, Blood.

Disease-Free Survival After Cord Blood (CB) Transplantation Is Not Different to That After Related or Unrelated Donor Transplantation in Patients with Hematologic Malignancies.

M. Perales, R. Jenq, K. Hsu, 2009 .

Allogeneic Hematopoietic Stem Cell Transplant for HIV Patient's Plasmablastic Lymphoma: Case Report

G. Koehne, M. Ruiz, Jannelle Vicens, 2023, Current Problems in Cancer: Case Reports.

CD34-selected allogeneic hematopoietic stem cell transplantation for patients with relapsed, high-risk multiple myeloma

S. Devlin, A. Lesokhin, S. Giralt, 2015 .

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

S. Trudel, M. Tomasson, S. Iida, 2023, Nature Medicine.

Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity

S. Devlin, A. Lesokhin, I. Grundberg, 2018, Leukemia & lymphoma.

Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.

M. Tomasson, S. Iida, M. Mohty, 2023, Journal of Clinical Oncology.